On July 6, Pharmaron rose 5.12% in regular trading, trading at 20.36 HKD/share, with turnover of approximately 70.81 million HKD. The rally was driven by broad-based strength across the CXO sector combined with the company's strong operational momentum.

On the sector front, peers including WuXi XDC, XtalPi, and WuXi AppTec posted gains of 3.24%, 4.3%, and 1.35% respectively, reflecting notable sector-wide linkage effects. On the fundamental side, Pharmaron reported Q1 laboratory services new order growth exceeding 20% year-over-year, while small molecule CDMO orders surged over 50% year-over-year, primarily driven by projects advancing from early-stage to late-stage clinical phases, which amplified order values.

Additionally, the company recently disclosed a combined 5 billion yuan capacity expansion plan, comprising a 3 billion yuan pharmaceutical intermediate and API project in Shaoxing and a 2 billion yuan CDMO R&D production base in Hangzhou, signaling confidence in medium-to-long-term growth. International institutional investors including Ariel Investments and Norges Bank have also increased their holdings in recent months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)